CBAC-02 is under clinical development by CHA Biotech and currently in Phase II for Alzheimer’s Disease. According to GlobalData, Phase II drugs for Alzheimer’s Disease have a 36% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CBAC-02’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CBAC-02 is under development for the treatment of Alzheimer's disease and global cerebral ischemia. The therapy improves neuronal survival and neurogenesis, and prevents memory deficiency. It is administered through intravenous route. MSC is a multipotent stem cell with capacity for self-renewal and differentiation with broad tissue distribution. MSCs derived from placenta (PD-MSCs) possess higher proliferative capacity.
CHA Biotech overview
CHA Biotech, formerly CHA Bio & Diostech, is a biotechnology company that offers cell therapeutics development, bio insurance, cord blood, and stem cell banking solutions. Its R&D pipeline provides research in the therapeutic areas of age-related macular degeneration, intermittent claudication, stroke, Stargardt degeneration, Alzheimer’s disease, disk degeneration and others. CHA Biotech provides a bio-medical complex system that helps in managing cord blood collection, treatment, and transplantation; and also conducts ongoing research on cord blood-based therapeutics for treating incurable diseases using adult stem cells, embryonic stem cells and immune cells. The company also provides hospital IT management services across Japan. CHA Biotech is headquartered in Seongnam, Gyeonggido, South Korea.
For a complete picture of CBAC-02’s drug-specific PTSR and LoA scores, buy the report here.